In this specific article, we review latest data on the usage of EGFR inhibitors for treatment of individuals with CNS and NSCLC metastases. Keywords: Lung neoplasms, Epidermal growth point receptor, EGFR-tyrosine kinase inhibitors, Central anxious system metastases [1](non-small cell lung tumor, NSCLC)80%-85%, [2, 3], 5[4] NSCLC(central anxious system, CNS)30%-50%, , , 1, 2, 2-6[5-13] (epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs)NSCLCNSCLCEGFR30%-40%, 10%[14-17]EGFR-TKIsEGFRNSCLC56%-74%, (progression-free survival, PFS)10-14, [18-22]EGFR-TKIs, CNSEGFR-TKIsNSCLCCNS 1.?NSCLC CNS CNS, [23-27]NSCLC, , (), 2-3[28] 2.?NSCLC CNSEGFR-TKIs [18, 22, 29]NSCLCEGFR-TKIs70%-80%, PFS12, EGFR-TKIs, CNS[30]CNSEGFR-TKIs, EGFR-TKIsNSCLCCNS30%[31-34] [35]EGFR-TKIs, 12CNS6%19%EGFR, EGFREGFR-TKIs[36, 37]EGFREGFR, 11.75.8, 85%, EGFR16%[38][39], NSCLC, 16.7%EGFR, 31.3%, 52%, PFS10.1, PFS9.7, EGFRPFS15.2, EGFR4.4 EGFR-TKIsEGFR-TKIs, NSCLCEGFR-TKIsCNS, EGFR-TKIs[40] , CNS[41, 42], , CNS, P(P-glycoprotein, P-gp)[43-45] , EGFR-TKIsWeber[46]1NSCLC, 11, (positron emission tomography-computed tomography, PET-CT), EGFR-TKIsCNS, Togashi[47]OSI-420NSCLC5.1%5.8%, EGFR-TKIsJackman[48]1Jackman[49]10, CNS10%, CNSPFS1.7, , 3.?EGFR-TKIs EGFR-TKIsEGFR, [50]Petra Hoffknecht[51]CNS31NSCLC42%(13)(partial response, PR), 39%(12)(steady disease, SD), 19%(6)(progressive disease, PD) 45EGFRNSCLC76%, PFS18.2, EGFRNSCLC, [52]”type”:”clinical-trial”,”attrs”:”text”:”NCT02047747″,”term_id”:”NCT02047747″NCT02047747, EGFRNSCLC, [53] 4.?EGFR-TKIs EGFR-TKIs(T790)AZD9291, rociletinib(CO-1686), HM61713, AZD9291CO-1686T79061%64%[54, 55] Sequist[55]1CNSCO-1686Kim[56]AZD-9291, CNSHM61713T790, , CNS[57] 5.?AZD3759 AZD3759CNSEGFR-TKIs, , AZD3759[58] 6.? , EGFR, (anaplastic lymphoma kinase, ALK), ROS1RETHER2BRAF[59]Preusser[60], 48, 29(60.4%), 7664(84.2%), TP53(46.1%), KRAS(38.2%), CDKN2A(22.4%), EGFR(3.9%), PIK3CA(2.6%), BRAF(1.3%), SMO(1.3%) EGFR-TKIs, , , , . EGFREGFR-TKIs[36, 37]EGFREGFR, 11.75.8, 85%, EGFR16%[38][39], NSCLC, 16.7%EGFR, 31.3%, 52%, PFS10.1, PFS9.7, EGFRPFS15.2, EGFR4.4 EGFR-TKIsEGFR-TKIs, NSCLCEGFR-TKIsCNS, EGFR-TKIs[40] , CNS[41, 42], , CNS, P(P-glycoprotein, P-gp)[43-45] , EGFR-TKIsWeber[46]1NSCLC, 11, (positron emission tomography-computed tomography, PET-CT), EGFR-TKIsCNS, Togashi[47]OSI-420NSCLC5.1%5.8%, EGFR-TKIsJackman[48]1Jackman[49]10, CNS10%, CNSPFS1.7, , 3.?EGFR-TKIs EGFR-TKIsEGFR, [50]Petra Hoffknecht[51]CNS31NSCLC42%(13)(incomplete response, PR), 39%(12)(steady disease, SD), 19%(6)(intensifying disease, PD) 45EGFRNSCLC76%, PFS18.2, EGFRNSCLC, [52]”type”:”clinical-trial”,”attrs”:”text”:”NCT02047747″,”term_id”:”NCT02047747″NCT02047747, EGFRNSCLC, [53] 4.?EGFR-TKIs EGFR-TKIs(T790)AZD9291, rociletinib(CO-1686), HM61713, AZD9291CO-1686T79061%64%[54, 55] Sequist[55]1CNSCO-1686Kim[56]AZD-9291, CNSHM61713T790, , CNS[57] 5.?AZD3759 AZD3759CNSEGFR-TKIs, , AZD3759[58] 6.? , EGFR, (anaplastic lymphoma kinase, ALK), ROS1RETHER2BRAF[59]Preusser[60], 48, 29(60.4%), 7664(84.2%), TP53(46.1%), KRAS(38.2%), CDKN2A(22.4%), EGFR(3.9%), PIK3CA(2.6%), hJumpy BRAF(1.3%), SMO(1.3%) EGFR-TKIs, , , , .However the systemic efcacy of targeted agents is set up, the efcacy of central nervous system (CNS) metastases isn’t aswell characterized. 2-6[5-13] (epidermal development aspect receptor tyrosine kinase inhibitors, EGFR-TKIs)NSCLCNSCLCEGFR30%-40%, 10%[14-17]EGFR-TKIsEGFRNSCLC56%-74%, (progression-free success, PFS)10-14, [18-22]EGFR-TKIs, CNSEGFR-TKIsNSCLCCNS 1.?NSCLC CNS CNS, [23-27]NSCLC, , (), 2-3[28] 2.?NSCLC CNSEGFR-TKIs [18, 22, 29]NSCLCEGFR-TKIs70%-80%, PFS12, EGFR-TKIs, CNS[30]CNSEGFR-TKIs, EGFR-TKIsNSCLCCNS30%[31-34] [35]EGFR-TKIs, 12CNS6%19%EGFR, EGFREGFR-TKIs[36, 37]EGFREGFR, 11.75.8, 85%, EGFR16%[38][39], NSCLC, 16.7%EGFR, 31.3%, 52%, PFS10.1, PFS9.7, EGFRPFS15.2, EGFR4.4 EGFR-TKIsEGFR-TKIs, NSCLCEGFR-TKIsCNS, EGFR-TKIs[40] , CNS[41, 42], , CNS, P(P-glycoprotein, P-gp)[43-45] , EGFR-TKIsWeber[46]1NSCLC, 11, (positron emission tomography-computed tomography, PET-CT), EGFR-TKIsCNS, Togashi[47]OSI-420NSCLC5.1%5.8%, EGFR-TKIsJackman[48]1Jackman[49]10, CNS10%, CNSPFS1.7, , 3.?EGFR-TKIs EGFR-TKIsEGFR, [50]Petra Hoffknecht[51]CNS31NSCLC42%(13)(incomplete response, PR), 39%(12)(steady disease, SD), 19%(6)(intensifying disease, PD) 45EGFRNSCLC76%, PFS18.2, EGFRNSCLC, [52]”type”:”clinical-trial”,”attrs”:”text”:”NCT02047747″,”term_id”:”NCT02047747″NCT02047747, EGFRNSCLC, [53] 4.?EGFR-TKIs EGFR-TKIs(T790)AZD9291, rociletinib(CO-1686), HM61713, AZD9291CO-1686T79061%64%[54, 55] Sequist[55]1CNSCO-1686Kim[56]AZD-9291, CNSHM61713T790, , CNS[57] 5.?AZD3759 AZD3759CNSEGFR-TKIs, , AZD3759[58] 6.? , EGFR, (anaplastic lymphoma kinase, ALK), ROS1RETHER2BRAF[59]Preusser[60], 48, 29(60.4%), 7664(84.2%), TP53(46.1%), KRAS(38.2%), CDKN2A(22.4%), EGFR(3.9%), PIK3CA(2.6%), BRAF(1.3%), Aminophylline SMO(1.3%) EGFR-TKIs, , , , .In this specific article, we review latest data on the usage of EGFR inhibitors for treatment of sufferers with NSCLC and CNS metastases. Keywords: Lung neoplasms, Epidermal growth matter receptor, EGFR-tyrosine kinase inhibitors, Central anxious system metastases [1](non-small cell lung cancers, NSCLC)80%-85%, [2, 3], 5[4] NSCLC(central anxious system, CNS)30%-50%, , , 1, 2, 2-6[5-13] (epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs)NSCLCNSCLCEGFR30%-40%, 10%[14-17]EGFR-TKIsEGFRNSCLC56%-74%, (progression-free survival, PFS)10-14, [18-22]EGFR-TKIs, CNSEGFR-TKIsNSCLCCNS 1.?NSCLC CNS CNS, [23-27]NSCLC, , (), 2-3[28] 2.?NSCLC CNSEGFR-TKIs [18, 22, 29]NSCLCEGFR-TKIs70%-80%, PFS12, EGFR-TKIs, CNS[30]CNSEGFR-TKIs, EGFR-TKIsNSCLCCNS30%[31-34] [35]EGFR-TKIs, 12CNS6%19%EGFR, EGFREGFR-TKIs[36, 37]EGFREGFR, 11.75.8, 85%, EGFR16%[38][39], NSCLC, 16.7%EGFR, 31.3%, 52%, PFS10.1, PFS9.7, EGFRPFS15.2, EGFR4.4 EGFR-TKIsEGFR-TKIs, NSCLCEGFR-TKIsCNS, EGFR-TKIs[40] , CNS[41, 42], , CNS, P(P-glycoprotein, P-gp)[43-45] , EGFR-TKIsWeber[46]1NSCLC, 11, (positron emission tomography-computed tomography, PET-CT), EGFR-TKIsCNS, Togashi[47]OSI-420NSCLC5.1%5.8%, EGFR-TKIsJackman[48]1Jackman[49]10, CNS10%, CNSPFS1.7, , 3.?EGFR-TKIs EGFR-TKIsEGFR, [50]Petra Hoffknecht[51]CNS31NSCLC42%(13)(partial response, PR), 39%(12)(steady disease, SD), 19%(6)(progressive disease, PD) 45EGFRNSCLC76%, PFS18.2, EGFRNSCLC, [52]”type”:”clinical-trial”,”attrs”:”text”:”NCT02047747″,”term_id”:”NCT02047747″NCT02047747, EGFRNSCLC, [53] 4.?EGFR-TKIs EGFR-TKIs(T790)AZD9291, rociletinib(CO-1686), HM61713, AZD9291CO-1686T79061%64%[54, 55] Sequist[55]1CNSCO-1686Kim[56]AZD-9291, Aminophylline CNSHM61713T790, , CNS[57] 5.?AZD3759 AZD3759CNSEGFR-TKIs, , AZD3759[58] 6.? , EGFR, (anaplastic lymphoma kinase, ALK), ROS1RETHER2BRAF[59]Preusser[60], 48, 29(60.4%), 7664(84.2%), TP53(46.1%), KRAS(38.2%), CDKN2A(22.4%), EGFR(3.9%), PIK3CA(2.6%), BRAF(1.3%), SMO(1.3%) EGFR-TKIs, , , , . 16.7%EGFR, 31.3%, 52%, PFS10.1, PFS9.7, EGFRPFS15.2, EGFR4.4 EGFR-TKIsEGFR-TKIs, NSCLCEGFR-TKIsCNS, EGFR-TKIs[40] , CNS[41, 42], , CNS, P(P-glycoprotein, P-gp)[43-45] , EGFR-TKIsWeber[46]1NSCLC, 11, (positron emission tomography-computed tomography, PET-CT), EGFR-TKIsCNS, Togashi[47]OSI-420NSCLC5.1%5.8%, EGFR-TKIsJackman[48]1Jackman[49]10, CNS10%, CNSPFS1.7, , 3.?EGFR-TKIs EGFR-TKIsEGFR, [50]Petra Hoffknecht[51]CNS31NSCLC42%(13)(incomplete response, PR), 39%(12)(steady disease, SD), 19%(6)(intensifying disease, PD) 45EGFRNSCLC76%, PFS18.2, EGFRNSCLC, [52]”type”:”clinical-trial”,”attrs”:”text”:”NCT02047747″,”term_id”:”NCT02047747″NCT02047747, EGFRNSCLC, [53] 4.?EGFR-TKIs EGFR-TKIs(T790)AZD9291, rociletinib(CO-1686), HM61713, AZD9291CO-1686T79061%64%[54, 55] Sequist[55]1CNSCO-1686Kim[56]AZD-9291, CNSHM61713T790, , CNS[57] 5.?AZD3759 AZD3759CNSEGFR-TKIs, , AZD3759[58] 6.? , EGFR, (anaplastic lymphoma kinase, ALK), ROS1RETHER2BRAF[59]Preusser[60], 48, 29(60.4%), 7664(84.2%), TP53(46.1%), KRAS(38.2%), CDKN2A(22.4%), EGFR(3.9%), PIK3CA(2.6%), BRAF(1.3%), SMO(1.3%) EGFR-TKIs, , , , .In this specific article, we review latest data on the usage of EGFR inhibitors for treatment of sufferers with NSCLC and CNS metastases. Keywords: Lung neoplasms, Epidermal growth matter receptor, EGFR-tyrosine kinase inhibitors, Central anxious system metastases [1](non-small cell lung cancers, NSCLC)80%-85%, [2, 3], 5[4] NSCLC(central anxious system, CNS)30%-50%, , , 1, 2, 2-6[5-13] (epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs)NSCLCNSCLCEGFR30%-40%, 10%[14-17]EGFR-TKIsEGFRNSCLC56%-74%, (progression-free survival, PFS)10-14, [18-22]EGFR-TKIs, CNSEGFR-TKIsNSCLCCNS 1.?NSCLC CNS CNS, [23-27]NSCLC, , (), 2-3[28] 2.?NSCLC CNSEGFR-TKIs [18, 22, 29]NSCLCEGFR-TKIs70%-80%, PFS12, EGFR-TKIs, CNS[30]CNSEGFR-TKIs, EGFR-TKIsNSCLCCNS30%[31-34] [35]EGFR-TKIs, 12CNS6%19%EGFR, EGFREGFR-TKIs[36, 37]EGFREGFR, 11.75.8, 85%, EGFR16%[38][39], NSCLC, 16.7%EGFR, Aminophylline 31.3%, 52%, PFS10.1, PFS9.7, EGFRPFS15.2, EGFR4.4 EGFR-TKIsEGFR-TKIs, NSCLCEGFR-TKIsCNS, EGFR-TKIs[40] , CNS[41, 42], , CNS, P(P-glycoprotein, P-gp)[43-45] , EGFR-TKIsWeber[46]1NSCLC, 11, (positron emission tomography-computed tomography, PET-CT), EGFR-TKIsCNS, Togashi[47]OSI-420NSCLC5.1%5.8%, EGFR-TKIsJackman[48]1Jackman[49]10, CNS10%, CNSPFS1.7, , 3.?EGFR-TKIs EGFR-TKIsEGFR, [50]Petra Hoffknecht[51]CNS31NSCLC42%(13)(partial response, PR), 39%(12)(steady disease, SD), 19%(6)(progressive disease, PD) 45EGFRNSCLC76%, PFS18.2, EGFRNSCLC, [52]”type”:”clinical-trial”,”attrs”:”text”:”NCT02047747″,”term_id”:”NCT02047747″NCT02047747, EGFRNSCLC, [53] 4.?EGFR-TKIs EGFR-TKIs(T790)AZD9291, rociletinib(CO-1686), HM61713, AZD9291CO-1686T79061%64%[54, 55] Sequist[55]1CNSCO-1686Kim[56]AZD-9291, CNSHM61713T790, , CNS[57] 5.?AZD3759 AZD3759CNSEGFR-TKIs, , AZD3759[58] 6.? , EGFR, (anaplastic lymphoma kinase, ALK), ROS1RETHER2BRAF[59]Preusser[60], 48, 29(60.4%), 7664(84.2%), TP53(46.1%), KRAS(38.2%), CDKN2A(22.4%), EGFR(3.9%), PIK3CA(2.6%), BRAF(1.3%), SMO(1.3%) EGFR-TKIs, , , , . EGFR-TKIsEGFR-TKIs, NSCLCEGFR-TKIsCNS, EGFR-TKIs[40] , CNS[41, 42], , CNS, P(P-glycoprotein, P-gp)[43-45] , EGFR-TKIsWeber[46]1NSCLC, 11, (positron emission tomography-computed tomography, PET-CT), EGFR-TKIsCNS, Togashi[47]OSI-420NSCLC5.1%5.8%, EGFR-TKIsJackman[48]1Jackman[49]10, CNS10%, CNSPFS1.7, , 3.?EGFR-TKIs EGFR-TKIsEGFR, [50]Petra Hoffknecht[51]CNS31NSCLC42%(13)(incomplete response, PR), 39%(12)(steady disease, SD), 19%(6)(intensifying disease, PD) 45EGFRNSCLC76%, PFS18.2, EGFRNSCLC, [52]”type”:”clinical-trial”,”attrs”:”text”:”NCT02047747″,”term_id”:”NCT02047747″NCT02047747, EGFRNSCLC, [53] 4.?EGFR-TKIs EGFR-TKIs(T790)AZD9291, rociletinib(CO-1686), HM61713, AZD9291CO-1686T79061%64%[54, 55] Sequist[55]1CNSCO-1686Kim[56]AZD-9291, CNSHM61713T790, , CNS[57] 5.?AZD3759 AZD3759CNSEGFR-TKIs, , AZD3759[58] 6.? , EGFR, (anaplastic lymphoma kinase, ALK), ROS1RETHER2BRAF[59]Preusser[60], 48, 29(60.4%), 7664(84.2%), TP53(46.1%), KRAS(38.2%), CDKN2A(22.4%), EGFR(3.9%), PIK3CA(2.6%), BRAF(1.3%), SMO(1.3%) EGFR-TKIs, , , , .In this specific article, we review latest data on the usage of EGFR inhibitors for treatment of sufferers with NSCLC and CNS metastases. Keywords: Lung neoplasms, Epidermal growth matter receptor, EGFR-tyrosine kinase inhibitors, Central anxious system metastases [1](non-small cell lung cancers, NSCLC)80%-85%, [2, 3], 5[4] NSCLC(central anxious system, CNS)30%-50%, , , 1, 2, 2-6[5-13] (epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs)NSCLCNSCLCEGFR30%-40%, 10%[14-17]EGFR-TKIsEGFRNSCLC56%-74%, (progression-free survival, PFS)10-14, [18-22]EGFR-TKIs, CNSEGFR-TKIsNSCLCCNS 1.?NSCLC CNS CNS, [23-27]NSCLC, , (), 2-3[28] 2.?NSCLC CNSEGFR-TKIs [18, 22, 29]NSCLCEGFR-TKIs70%-80%, PFS12, EGFR-TKIs, CNS[30]CNSEGFR-TKIs, EGFR-TKIsNSCLCCNS30%[31-34] [35]EGFR-TKIs, 12CNS6%19%EGFR, EGFREGFR-TKIs[36, 37]EGFREGFR, 11.75.8, 85%, EGFR16%[38][39], NSCLC, 16.7%EGFR, 31.3%, 52%, PFS10.1, PFS9.7, EGFRPFS15.2, EGFR4.4 EGFR-TKIsEGFR-TKIs, NSCLCEGFR-TKIsCNS, EGFR-TKIs[40] , CNS[41, 42], , CNS, P(P-glycoprotein, P-gp)[43-45] , EGFR-TKIsWeber[46]1NSCLC, 11, (positron emission tomography-computed tomography, PET-CT), EGFR-TKIsCNS, Togashi[47]OSI-420NSCLC5.1%5.8%, EGFR-TKIsJackman[48]1Jackman[49]10, CNS10%, CNSPFS1.7, , 3.?EGFR-TKIs EGFR-TKIsEGFR, [50]Petra Hoffknecht[51]CNS31NSCLC42%(13)(partial response, PR), 39%(12)(steady disease, SD), 19%(6)(progressive disease, PD) 45EGFRNSCLC76%, PFS18.2, EGFRNSCLC, [52]”type”:”clinical-trial”,”attrs”:”text”:”NCT02047747″,”term_id”:”NCT02047747″NCT02047747, EGFRNSCLC, [53] 4.?EGFR-TKIs EGFR-TKIs(T790)AZD9291, rociletinib(CO-1686), HM61713, AZD9291CO-1686T79061%64%[54, 55] Sequist[55]1CNSCO-1686Kim[56]AZD-9291, CNSHM61713T790, , CNS[57] 5.?AZD3759 AZD3759CNSEGFR-TKIs, , AZD3759[58] 6.? , EGFR, (anaplastic lymphoma kinase, ALK), ROS1RETHER2BRAF[59]Preusser[60], 48, 29(60.4%), 7664(84.2%), TP53(46.1%), KRAS(38.2%), Aminophylline CDKN2A(22.4%), EGFR(3.9%), PIK3CA(2.6%), BRAF(1.3%), SMO(1.3%) EGFR-TKIs, , , , . CNS, P(P-glycoprotein, P-gp)[43-45] , EGFR-TKIsWeber[46]1NSCLC, 11, (positron emission tomography-computed tomography, PET-CT), EGFR-TKIsCNS, Togashi[47]OSI-420NSCLC5.1%5.8%, EGFR-TKIsJackman[48]1Jackman[49]10, CNS10%, CNSPFS1.7, , 3.?EGFR-TKIs EGFR-TKIsEGFR, [50]Petra Hoffknecht[51]CNS31NSCLC42%(13)(incomplete response, PR), 39%(12)(steady disease, SD), 19%(6)(intensifying disease, PD) 45EGFRNSCLC76%, PFS18.2, EGFRNSCLC, [52]”type”:”clinical-trial”,”attrs”:”text”:”NCT02047747″,”term_id”:”NCT02047747″NCT02047747, EGFRNSCLC, [53] 4.?EGFR-TKIs EGFR-TKIs(T790)AZD9291, rociletinib(CO-1686), HM61713, AZD9291CO-1686T79061%64%[54, 55] Sequist[55]1CNSCO-1686Kim[56]AZD-9291, CNSHM61713T790, , CNS[57] 5.?AZD3759 AZD3759CNSEGFR-TKIs, , AZD3759[58] 6.? , EGFR, (anaplastic lymphoma kinase, ALK), ROS1RETHER2BRAF[59]Preusser[60], 48, 29(60.4%), 7664(84.2%), TP53(46.1%), KRAS(38.2%), CDKN2A(22.4%), EGFR(3.9%), PIK3CA(2.6%), BRAF(1.3%), SMO(1.3%) EGFR-TKIs, , , , .